<DOC>
	<DOC>NCT02042612</DOC>
	<brief_summary>Describing a pharmacokinetic model of 48-h sevoflurane sedation in obese ICU patients</brief_summary>
	<brief_title>Pharmacokinetic Study of 48-hour Sevoflurane Inhalation Using a Disposable Delivery System (AnaConDa©) in Obese ICU Patients</brief_title>
	<detailed_description>Prospective clinical monocentric study in ICU with sedated ventilated obese patients with sevoflurane during 48 h with the AnaConda® system, establishing pharmacokinetic model of sévoflurane and its metabolites (hydroxyfluroisopropanol, fluoride)</detailed_description>
	<mesh_term>Sevoflurane</mesh_term>
	<criteria>Adult patients ventilated more than 48 h Stable respiratory and hemodynamic conditions Consent of patients or family Arterial line BMI &gt;30 Acute kidney injury BMI &lt;30 Sevoflurane anaphylaxia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Sevoflurane</keyword>
	<keyword>Obesity</keyword>
	<keyword>Sedation</keyword>
	<keyword>ICU patients</keyword>
</DOC>